Home > Oncology > ASCO 2021 > Gastrointestinal Cancers > Benefit of both I-O/chemo combo and I-O/I-O combo over chemotherapy alone in oesophageal squamous cell cancer

Benefit of both I-O/chemo combo and I-O/I-O combo over chemotherapy alone in oesophageal squamous cell cancer

Presented By
Dr Ian Chau, Royal Marsden Hospital, UK
Conference
ASCO 2021
Trial
Phase 3, CheckMate 648
First results of the randomised, phase 3 CheckMate 648 study demonstrated superior overall survival of first-line treatment with nivolumab plus ipilimumab or nivolumab plus chemotherapy versus chemotherapy alone. Standard first-line chemotherapy for advanced or metastatic oesophageal squamous cell cancer (ESCC) results in poor overall survival [1]. Recently, first-line treatment with the PD-1 inhibitor nivolumab demonstrated superior overall survival versus chemotherapy in previously treated patients with ESCC in the ATTRACTION-3 trial (NCT02569242) [2]. The randomised, phase 3 CheckMate 648 trial (NCT03143153) explored the efficacy and safety of first-line treatment in ESCC with 2 combination therapies: nivolumab plus ipilimumab (I-O/I-O combo) and nivolumab plus chemotherapy (I-O/chemo combo). Enrolled were 970 patients with ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on